{"filing":{"accession_number":"0001193125-26-311357","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"d173035d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/d173035d8k.htm"},"events":[{"id":19358,"run_id":17419,"accession_number":"0001193125-26-311357","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"LB Pharmaceuticals announced an acceleration of the Phase 3 NOVA-2 trial topline results timeline from H2 2027 to H1 2027, driven by faster-than-expected enrollment. This is a material operational/clinical development milestone for a clinical-stage biotech company whose value depends heavily on pipeline progress. While not a specific named event type, this represents a significant positive update to the company's clinical development pathway and regulatory timeline that would affect investor assessment of the registrant's prospects.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18429,"accession_number":"0001193125-26-311357","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"LB Pharmaceuticals announced an acceleration of the Phase 3 NOVA-2 trial topline results timeline from H2 2027 to H1 2027, driven by faster-than-expected enrollment. This is a material operational/clinical development milestone for a clinical-stage biotech company whose value depends heavily on pipeline progress. While not a specific named event type, this represents a significant positive update to the company's clinical development pathway and regulatory timeline that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:15:37.804193+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18429,"accession_number":"0001193125-26-311357","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"LB Pharmaceuticals announced an acceleration of the Phase 3 NOVA-2 trial topline results timeline from H2 2027 to H1 2027, driven by faster-than-expected enrollment. This is a material operational/clinical development milestone for a clinical-stage biotech company whose value depends heavily on pipeline progress. While not a specific named event type, this represents a significant positive update to the company's clinical development pathway and regulatory timeline that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:15:37.804193+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-22"}]}